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Murine models of severe acute respiratory syn-
drome–associated coronavirus (SARS-CoV) will greatly
advance research on this emerging virus. When BALB/c
mice were simultaneously inoculated intranasally and oral-
ly, replication of SARS-CoV was found in both lung and
intestinal tissue.
T
he outbreak of severe acute respiratory syndrome
(SARS) that emerged in China in November 2002 was
caused by a novel coronavirus (SARS-CoV) that was
detected in lungs, nasopharyngeal aspirates, and feces of
infected patients (1–4). This outbreak in humans is striking
because of the high rate of illness and death associated
with it. The SARS-CoV outbreak likely resulted from
zoonotic transmission, and natural animal reservoirs of
viruses nearly identical to SARS-CoV increase the likeli-
hood of its reemergence in humans (5). 
Coronaviruses are enveloped, plus-stranded RNA
viruses that cause important respiratory and enteric dis-
eases of humans and many animal species. Large peplom-
ers or spike glycoproteins (S) are the viral attachment
proteins that protrude from the virion and give it the
appearance of a corona. Coronaviruses are members of the
Nidovirales, which produce 3′ co-terminal nested subge-
nomic mRNAs upon entry into susceptible host cells. The
genome is the largest of all RNA viruses (27.6–31.2 kb),
and the genomic RNA is infectious when transfected into
cells from a wide variety of species and tissue types. Yet
most strains of coronavirus have very restricted species
and tissue tropism, illustrating the major role S-receptor
interactions play in the species specificity and pathogene-
sis of coronaviruses. SARS-CoV sequence analysis shows
that it has many of the unique characteristics of coron-
aviruses and that it shares the most predicted amino acid
similarity and other molecular signatures with serogroup 2
coronaviruses (6). 
Animal models of SARS-CoV are important for the
study of virus-host interactions. Cats, ferrets, and nonhu-
man primates have been experimentally infected with
SARS-CoV (7,8). In addition, SARS-CoV–like viruses
were isolated from palm civet cats and closely related rac-
coon dogs, which are sold in markets in China (5). All of
these animal species are important for the in vivo study of
SARS-CoV. However, a murine model is also necessary to
evaluate antiviral agents, vaccines, and immune response.
Previous studies in suckling mice inoculated intracranially
or intraperitoneally suggest that mice are not permissive to
SARS-CoV (1,8). On the other hand, the infection of
divergent species suggests that many animal species may
be susceptible (5,8).
Human and animal coronaviruses are transmitted by the
respiratory or enteric routes and initially infect epithelial
cells of these tissues (9). Thus, a combined intranasal and
oral injection of mice was explored as a potential animal
model for SARS-CoV. Four-week-old, female BALB/c
mice were inoculated intranasally and orally with 2 x 105
50% tissue culture infective dose of SARS-CoV Urbani or
were mock-inoculated with carrier alone. Mice were
weighed and observed for clinical signs daily throughout
the study. Three SARS-CoV–inoculated and one mock-
inoculated mouse were euthanized 3, 5, 7, 10, and 28 days
postinoculation (p.i.). Tissues harvested on euthanasia
included blood, lungs, and small intestine (ileum). Total
RNA was isolated from the lungs and intestines. All work
with mice was conducted at the Wadsworth Center, New
York Department of Health, Albany, under a protocol
approved by the Institutional Animal Care and Use
Committee. All experiments with infectious SARS-CoV
were performed in a biosafety level 3 laboratory and were
conducted under appropriate conditions, with precautions
that adhered to, or exceeded, the requirements set forth in
“Interim Laboratory Biosafety Guidelines for Handling
and Processing Specimens Associated with SARS” (avail-
able from www.cdc.gov/ncidod/sars/sarslabguide.htm). 
To specifically identify virus replication, a multiplex
reverse transcriptase–polymerase chain reaction (RT-PCR)
was used to simultaneously amplify glyceraldehyde 3
phosphate dehydrogenase (G3PDH), SARS-CoV genomic
RNA(gRNA), and subgenomic RNA(sgRNA) (10). Upon
entry into host cells the coronavirus gRNA (27–31.5 kb)
serves as an mRNA to translate two large polyproteins (1a
and 1ab). The polyproteins are autocatalytically processed
into replicative enzymes, including the RNA-dependent
RNA polymerase, which synthesizes both negative-sense
and positive-sense sgRNAs, and the positive-sense
sgRNAs serve as mRNAs for all of the open reading
frames (ORFs) downstream of ORF1b (6,11). SARS-CoV
infects Vero, Vero E6, and primary rhesus monkey kidney
cells in culture, and infected cells have a nested set of eight
3′ co-terminal of mRNAs, each of which has at its 5′ end a
leader sequence derived from the 5′ terminus of the
genome (6,12). We took advantage of the unique features
of CoV replication, sgRNA transcription in particular, to
develop multiplex primers to differentiate input gRNA
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A 180-bp amplicon is produced from a sense primer
(SARS-1 [5′-ATATTAGGTTTTTACCTACCCAGG-3′])
that is specific for the leader sequence and an antisense
primer specific for the SARS-CoVspike glycoprotein gene
(SARS-21,593R [5′-AGTATGTTGAGTGTAATTAG-
GAG-3′]). This amplicon is produced only when sgRNAis
present and indicates virus entry and replication. To iden-
tify gRNA (input and newly synthesized), a sense primer
that binds the 3′ terminus of the 1b gene (SARS-21,263
[5′- TGCTAACTACATTTTCTGGAGG-3′] was paired
with SARS-21,593R to produce a 276-bp amplicon. The
amplification was performed as a multiplex reaction for
SARS-CoV gRNA, sgRNA, and G3PDH by using a
OneStep RT-PCR procedure (Qiagen, Inc., Valencia, CA);
thus, both positive- and negative-sense SARS-CoV RNAs
served as templates for reverse transcription. 
Production and persistence of gRNA and sgRNA were
examined in permissive and nonpermissive cells. Analysis
of permissive Vero E6 cells showed that the sgRNAencod-
ing S was not present in the input virus before RNA repli-
cation (Figure 1A, 1 h). However, S sgRNAs produced
after entry were detected at 16 h and 5 d after SARS-CoV
inoculation. Additionally, gRNA qualitatively increased
after entry of the virus. In contrast, sgRNAwas not detect-
ed in nonpermissive murine (L2) or human (MRC5) cell
lines, and gRNA fell below detectable limits by 5 d. The
reaction conditions were optimized to favor amplification
of SARS-CoV gRNA and sgRNA; thus, when they were
present at high levels, amplification of G3PDH was
reduced. Amplification of G3PDH was used to demon-
strate RNA integrity, and it was always detected in the
absence of viral RNAs. 
Lungs from the experimentally inoculated mice were
analyzed by the multiplex assay. One of three mice from
each group sacrificed on days 3, 5, and 7 p.i. showed evi-
dence of lung infection (Figure 1B). The presence of
gRNA on days 5 and 7 is strong evidence for viral replica-
tion since the inoculum is most likely degraded, as is seen
with nonpermissive cells in vitro (Figure 1A). In addition,
sgRNA, which is indicative of virus replication, was
amplified from the lung RNA of a mouse on day 7 p.i.
(Figure 1B, sgRNA). Heminested PCR of the first-round
multiplex RT-PCR amplicons showed that SARS-CoV
gRNA and sgRNA were present in the lungs of each of
these mice. Another animal euthanized 5 days p.i. also
showed evidence of infection by the heminested PCR
(Figure 1B, HN). SARS-CoV gRNA or sgRNA was not
detected in the lungs of mice 10 days p.i. or in any mock-
inoculated animals (Figure 1). Infection of lung tissue in
mice is consistent with the tropism of SARS-CoV in
humans and experimentally inoculated nonhuman pri-
mates, ferrets, and cats (4,7,8). 
Coronaviruses of many animal species, including
porcine, feline, canine, murine, and bovine, infect intestin-
al tissue (9). In humans, SARS-CoV causes interstitial
pneumonia with fever and sometimes diarrhea (3,4). In our
study, SARS-CoV gRNA was present in the intestines of
all virus-inoculated mice at 3 and 5 days p.i. (Figure 1B).
Heminested PCR of these amplicons showed that sgRNA
was also present in all virus-inoculated animals on days 3
and 5. One mouse had sgRNAin the ileum 7 days p.i.; this
same mouse that had qualitatively high levels of gRNA
and sgRNA in the lung (mouse 12). Identification of
SARS-CoV replication in the small intestines of mice is
consistent with the enteric disease observed in some
human SARS-CoV infections and with the identification
of SARS-CoV gRNA in the stomach and duodenum of an
experimentally infected cynomolgus  macaque (4,7).
The mice were assessed for clinical disease and weight
loss. Subtle clinical disease was observed in some of the
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Figure 1. Replication-specific multiplex reverse transcriptase–
polymerase chain reaction (RT-PCR) assay shows severe acute
respiratory syndrome–associated coronavirus (SARS-CoV) repli-
cated in the lungs and intestines of mice. A) Vero E6, murine
fibroblast (L2), and human lung fibroblasts (MRC5) were inoculat-
ed with SARS-CoV at an MOI of ≈0.001 or were mock-inoculated
(M). G3PDH, SARS-CoV gRNA, and sgRNA were amplified by
multiplex RT-PCR from total RNA extracted at 1 h, 16 h, or 5 days
after inoculation. Amplicons were visualized by ethidium bromide
staining after electrophoresis; negative images are shown. B) Mice
were inoculated with 2x105 50% tissue culture infective dose of
SARS-CoV (lanes labeled 6–17) or were mock-inoculated (M) and
euthanized after 3, 5, 7, or 10 days. G3PDH, SARS-CoV gRNA,
and sgRNA were amplified by multiplex RT-PCR from total RNA
extracted from the lung (L) and intestine (I) harvested at various
time points. Heminested PCR (HN) was used to amplify gRNAand
sgRNA from RT-PCR reactions. Positive and negative controls for
PCR reactions are indicated by + and –, respectively. D indicates
DNA marker ladder. *The doublet observed in HN-PCR reactions
results from residual primers used in the primary amplification
reaction.mice; four mice had ruffled fur for >3 days, including
mouse 12, which had qualitatively high levels of gRNA
and sgRNAin its lung (Figure 1B). No respiratory distress
or diarrhea was observed throughout the study. The virus-
inoculated mice tended to gain less weight than the mock-
inoculated mice (Figure 2A). In addition, 3 of 15 mice lost
5%–6% body weight 3 days p.i., and 1 of 9 mice lost 6%
body weight on day 7. Overall, six mice exhibited either
mild clinical signs or weight loss throughout the study,
while mock-inoculated mice remained unaffected. This
finding suggests that SARS-CoV caused a subclinical
infection or a very mild disease in mice. 
Serum antibody to SARS-CoV was analyzed by a virus
neutralization assay (Figure 2B). Mock-inoculated mice
showed no virus neutralization, nor was neutralizing anti-
body detected in mice euthanized 3 or 5 days p.i.
Neutralizing antibodies were detected in all mice sacri-
ficed 7, 10, and 28 days p.i., and the titers were 8- to 16-
fold higher on day 28. These neutralizing titers are similar
to those reported for naturally and experimentally infected
animals (5,8). In addition, seroconversion to SARS-CoV is
the accepted standard for the determination of human
infections by SARS-CoVand continues to be more reliable
than RT-PCR methods (4). 
The presence of gRNA and, more importantly, sgRNA
in the lungs and intestines shows that SARS-CoV replicat-
ed in these tissues. Furthermore, the high neutralizing anti-
body titers on day 28 p.i. are supportive of an active viral
infection. The presence of SARS-CoV RNAs or neutraliz-
ing antibodies demonstrates that all 15 inoculated mice
were infected. The results of this study suggest that SARS-
CoV peaks early (days 3–5), and the immune response
clears the virus from the lung and intestine by 10 days,
which suggsts that viral clearance in mice is more rapid
than in human patients, who begin to recover 7–12 days
after the onset of clinical illness (approximately 9–14 days
after infection) (3,4). In 10% to 15% of patients, the initial
phase of disease is followed by more severe pulmonary
disease characterized by respiratory distress, pulmonary
infiltration of mononuclear inflammatory cells, multinu-
cleated syncytia, and fibrosis (3,4). The pathophysiology
of the late complications of SARS is not understood, but
immunopathology could play a critical role in the disease.
This study opens many potential avenues of research using
wild-type, transgenic, or knockout mice to answer ques-
tions of how age, sex, prior exposure, and immune
response influence the pathogenesis of SARS-CoV.
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(black squares) and virus-inoculated (gray bars with hatched
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